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ABSTRACT
The glucose transporter isoform 1 (GLUT1; SLC2A1) is a key rate-limiting factor in 
the transport of glucose into cancer cells. Enhanced GLUT1 expression and accelerated 
glycolysis have been found to promote aggressive growth in a range of tumor entities. 
However, it was unknown whether GLUT1 directly impacts metastasis. Here, we 
aimed at analyzing the expression and function of GLUT1 in malignant melanoma. 
Immunohistochemical analysis of 78 primary human melanomas on a tissue micro 
array showed that GLUT1 expression significantly correlated with the mitotic activity 
and a poor survival. To determine the functional role of GLUT1 in melanoma, we 
stably suppressed GLUT1 in the murine melanoma cell line B16 with shRNA. GLUT1 
suppressed melanoma cells revealed significantly reduced proliferation, apoptosis 
resistance, migratory activity and matrix metalloproteinase 2 (MMP2) expression. 
In a syngeneic murine model of hepatic metastasis, GLUT1-suppressed cells formed 
significantly less metastases and showed increased apoptosis compared to metastases 
formed by control cells. Treatment of four different human melanoma cell lines with a 
pharmacological GLUT1 inhibitor caused a dose-dependent reduction of proliferation, 
apoptosis resistance, migratory activity and MMP2 expression. Analysis of MAPK 
signal pathways showed that GLUT1 inhibition significantly decreased JNK activation, 
which regulates a wide range of targets in the metastatic cascade. In summary, our 
study provides functional evidence that enhanced GLUT1 expression in melanoma 
cells favors their metastatic behavior. These findings specify GLUT1 as an attractive 
therapeutic target and prognostic marker for this highly aggressive tumor.
INTRODUCTION
Melanoma is the most aggressive form of skin 
cancer. Even very thin primary tumors may seed 
metastases and precipitate rapid death [1, 2]. The 
worldwide incidence of melanoma is increasing more 
than in any other neoplastic disease [3]. Still, to date 
there is no effective therapy for metastatic melanoma and 
at the molecular level the disease progression is poorly 
understood [4].
In the 1920s, Otto Warburg made the observation 
that tumor cells utilize glycolysis instead of mitochondrial 
oxidative phosphorylation for energy production even 
under oxygen-rich conditions. Lately, the “Warburg effect” 
has experienced a revival, because it has been shown that 
aerobic glycolysis governs tumor cell biology [5, 6].
Oncotarget32749www.impactjournals.com/oncotarget
The glucose transporter isoform 1 (GLUT1; 
SLC2A1) is a key rate-limiting factor in the transport 
and metabolism of glucose in cancer cells. GLUT1 
expression is primarily undetectable in normal epithelial 
tissues and benign epithelial tumors. However, GLUT1 
is overexpressed in a significant proportion of human 
carcinomas [7-9]. The apparent expression of a certain 
type of glucose transporter suggests an important role for 
this transporter in tumor biology. Therefore, it has been 
hypothesized that elevated GLUT1 expression by human 
carcinomas indicates enhanced utilization of energy and an 
increased metabolic state. This may induce proliferation 
and tumor growth and herewith indirectly promote 
metastatic behavior. Actually, GLUT1 protein expression 
confers poor prognosis in a wide range of solid tumors 
[10-14] but experimental studies which functionally proof 
an impact of GLUT1 expression on metastasis are missing. 
Furthermore, malignant melanoma studies regarding 
GLUT1 expression have revealed inconclusive results 
and the biological significance of GLUT1 in disease 
progression has remained unknown [15-19]. 
Here, we aimed to analyze GLUT1 expression 
in a large series of benign nevi, primary melanomas 
and melanoma metastases and correlated GLUT1 
expression levels with clinicopathological characteristics. 
Furthermore, we analyzed the functional effect of GLUT1 
expression on growth and metastasis of melanoma cells in 
vitro and in vivo. Together, experimental and patients data 
show that enhanced GLUT1 expression advances both 
growth and metastasis of malignant melanoma.
RESULTS
GLUT1 expression in primary human melanoma 
and melanoma metastases
First, we analyzed GLUT1 expression in a series 
of 118 benign nevi, 78 primary human malignant 
Figure 1: GLUT1 expression in human nevi, primary malignant melanomas and melanoma metastases. GLUT1 
immunohistochemical staining was performed on a TMA comprising 123 benign nevi, 78 primary human malignant melanomas and 60 
melanoma metastases. Staining intensity was categorized into absent (0), weak (1+) and strong (2+). A. Representative images of primary 
tumors with the 3 different GLUT1 staining intensities are depicted in the right panel. Percentage of GLUT1 staining intensities in nevi, 
primary malignant melanomas and melanoma metastases (left panel). Kaplan-Meier tables showing B. progression free survival (PFS) and 
C. overall survival (OS) of melanoma patients with GLUT1 negative primary tumors (n = 39) and patients with GLUT1 positive (staining 
intensity 1+ or 2+) primary tumors (n = 39).
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melanomas, and 60 melanoma metastases applying 
GLUT1 immunohistochemistry and tissue microarray 
(TMA) technology [20]. In 65% (77/118) of the nevi no 
GLUT1 immunosignal was detectable, 35% (41/118) 
showed weak GLUT1 staining and in only one nevus 
strong GLUT1 staining was detectable (Figure 1A). 
In contrast, in only 50% (39/78) of primary melanoma 
tissues no GLUT1 immunosignal was detectable, 47% 
(37/78) showed at least weak staining and 2 tissues had 
a strong GLUT1 immunosignal (p = 0.038 compared 
to nevi) (Figure 1A). Melanoma metastases revealed 
an even stronger GLUT1 immunosignal compared to 
primary melanomas (p = 0.004). In only 42% (29/69) 
of metastases no GLUT1 immunosignal was detectable 
but 20% (12/69) showed strong GLUT1 staining (Figure 
1A). For descriptive data analysis, clinico-pathological 
characteristics of primary tumors were compared with 
GLUT1 immunohistochemistry (Table 1). Interestingly, 
GLUT1 expression significantly correlated with the 
proliferation rate (KI67 labeling index) of primary 
malignant melanomas. No correlation was found between 
GLUT1 expression and age and gender of melanoma 
patients or the Clark level, thickness, and the growth 
pattern of the primary tumors. Importantly, patients with 
GLUT1 positive tumors revealed a significantly lower 
progression free (PFS) and overall survival (OS) (Figure 
1B, 1C). Together, these data indicate that GLUT1 
expression correlates with metastasis and a poor prognosis 
in patients with malignant melanoma. 
Inhibition of GLUT1 expression in murine B16 
melanoma cells
To gain insight into the functional role of increased 
GLUT1 in melanoma cells, we inhibited GLUT1 
Table 1: Clinico-pathologic parameters in relation to GLUT1 immunohistochemistry (IHC)
 GLUT1 IHC
Variable Categorization analyzable(n) 0 (n) 1+ (n) 2+ (n) P
1
Primary malignant melanomas2 
Age at diagnosis
 ≤60 years 46 24 21 1 0.910
 >60 years 32 15 16 1
Gender
 female 41 16 24 1 0.074
 male 37 23 13 1
Clark level3
 I 1 0 1 0
 II 1 1 0 0
 III 10 4 6 0 0.930
 IV 50 25 23 2
V 15 8 7 0
Tumor thickness 
≤2.0mm 24 15 8 1 0.193
 >2.0mm 54 24 29 1
Growth pattern4
 NOS 13 6 7 0
 SSM 32 18 13 1
ALM 5 2 3 0 0.940
NMM 27 13 13 1
 LMM 1 0 1 0
Ki67 labeling index
 ≤5% 39 26 13 0 0.019
 >5% 22 8 12 2
1 Fisher’s exact test (two-sided), bold face representing significant data;
2 only initial and unifocal  malignant melanomas were included; 
3 according to UICC: TNM Classification of Malignant Tumours. 6th edn (2002), Sobin LH, Wittekind CH (eds.) 
Wiley, New York;    
4 NOS, not otherwise specified; SSM, superfical spreading melanoma; ALM, acral lentiginous melanoma; NMM, 
nodular malignant melanoma; LMM, lentigo maligna melanoma.
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expression in the murine melanoma cell line B16 by stable 
transfection with a shRNA expression vector containing 
the sequence of GLUT1 siRNA (GLUT1_shRNA1 and 
GLUT1_shRNA2). B16 cells transfected with the empty 
vector served as control. Quantitative RT-PCR and western 
blot analysis revealed a strong downregulation of GLUT1 
expression in GLUT1_shRNA compared to control cell 
clones (Figure 2A, 2B). Immunohistochemical analysis 
showed strong membranous GLUT1 staining in control 
cells, which almost completely disappeared in GLUT1 
shRNA transfected cell clones (Figure 2C). GLUT1 
suppressed cells revealed significantly reduced glucose 
uptake and consumption compared to control cells (Figure 
2D, 2E). In line with this, lactate secretion was reduced 
in GLUT1 suppressed cells (Figure 2F). Together, these 
data indicate that GLUT1 is a rate-limiting factor for the 
glucose transport and glycolysis in melanoma cells in 
vitro.
Effect of GLUT1 inhibition on B16 melanoma 
cells in vitro
To further characterize the role of GLUT1 in 
melanoma cells, we performed functional in vitro assays 
with GLUT1 suppressed and control B16 cells. All 
formed a homogenous cell layer and appeared similar 
in microscopical analysis (Suppl.Figure 1). However, 
GLUT1 suppression significantly reduced cell growth 
(Figure 3A, Suppl.Figure 2) and impaired mitochondrial 
activity as analyzed by XTT assay (Figure 3B). In 
addition, GLUT1 suppressed B16 cells had significantly 
higher caspase 3/7 activity (Figure 3C). Annexin V-FITC 
Figure 2: Inhibition of GLUT1 expression in B16 melanoma cells. A. Quantitative RT-PCR and B. western blot analysis of 
GLUT1 expression in B16 melanoma cells after stable transfection with an expression vector containing GLUT1 shRNA (shRNA1 or 
shRNA2). B16 cells transfected with the empty vector served as control (ctrl.). C. GLUT1 immunohistochemical staining of cell pellets 
of control and GLUT1 shRNA cell clones. D. Glucose uptake, E. glucose consumption and F. lactate secretion of GLUT1 suppressed and 
control cell clones. (*p < 0.05 compared to control).
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Figure 3: Effect of GLUT1 inhibition on B16 melanoma cells in vitro. A. Proliferation (as determined by cell counting), B. 
mitochondrial activity (XTT assay), C. caspase 3/7 activity assay and D. proportion of apoptotic cells (Annexin V-FITC FACS analysis) 
of GLUT1 suppressed and control cells. E. Analysis of migratory activity with Boyden chamber assays. F. Analysis of cell migration in 
time-lapse scratch assays (bar depicts the original width of the scratch). G. MMP2 mRNA expression levels of GLUT1 suppressed clones 
compared to control cells. H. Western blot analysis of phosphorylated JNK1/2 (Thr183/Tyr185) and c-JUN (Ser73) in GLUT1 suppressed 
and control cells. (*p < 0.05 compared to control). 
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FACS analysis confirmed a higher apoptosis rate in 
GLUT1 suppressed cells (Figure 3D, Suppl.Figure 
3). Interestingly, Boyden chamber assays (Figure 3E) 
and time-lapse scratch assays (Figure 3F, Suppl.Figure 
4) revealed significantly reduced migratory activity 
compared to control cells. Moreover, GLUT1 suppression 
in B16 cells led to a significant reduction of the expression 
of matrix metalloproteinase 2 (MMP2) (Figure 3G), which 
encodes for an enzyme involved in degradation of extra-
cellular matrix proteins and tumor progression. C-Jun 
N-terminal kinase (JNK; MAPK8) regulates a wide range 
of targets in the progression and metastatic cascade of 
cancer cells including proliferation, migration, attachment 
and MMP-expression [21, 22]. Notably, western blot 
analysis showed reduced levels of phosphorylated JNK 
and c-JUN in GLUT1 suppressed cell clones (Figure 
3H). In summary, these findings indicate that GLUT1 
expression in malignant melanoma cells promotes their 
tumorigenicity in vitro and that this is at least in part 
mediated via enhanced JNK-activity.
Effect of GLUT1 inhibition on hepatic metastasis 
of melanoma cells in vivo
To test the effect of GLUT1 on tumor metastasis in 
vivo, we employed an established syngeneic murine model 
of hepatic metastasis [23] using GLUT1 suppressed and 
control B16 cell clones. Macroscopic analysis showed 
less metastases on the liver surface of mice injected with 
GLUT1 suppressed cell clones (Figure 4A). Also serum 
levels of transaminases were significantly lower in these 
mice reflecting reduced hepatic tumor burden (Suppl.
Figure 5). Histological analysis confirmed that GLUT1 
suppressed melanoma cells formed significantly less 
hepatic metastases (Figure 4B). Furthermore, metastases 
derived from GLUT1 suppressed cell clones tended 
to be smaller, but differences did not reach the level of 
significance (Suppl.Figure 6). Quantitative RT-PCR 
analysis verified reduced GLUT1 mRNA expression 
in tumors formed by B16 cell clones stably transfected 
with GLUT1 shRNA (Figure 4D). Immunohistochemical 
analysis confirmed significantly stronger, membranous 
GLUT1 staining in vital areas of metastases formed 
by control cells clones compared to GLUT1 shRNA 
cell clones (Figure 4C). In both, control and GLUT1 
suppressed clones, staining intensity increased from the 
border of the metastases to the center (Figure 4C and 
Suppl.Figure 7). Most likely, this resulted from increased 
hypoxia in the center of the metastases, as GLUT1 
expression is known to be induced by hypoxia [24]. In line 
with the in vitro data, TUNEL staining revealed significant 
more apoptosis in hepatic metastases formed by GLUT1 
suppressed cells (Figure 4E). In summary, these data 
demonstrate that GLUT1 expression advances metastasis 
of melanoma cells in vivo.
Effect of chemical GLUT1 inhibition on 
proliferation of melanoma cells in vitro
The strongly impaired tumorigenicity of GLUT1 
suppressed cell clones compared to control cells indicated 
that GLUT1 inhibition is a valuable therapeutic target to 
inhibit growth and metastasis of malignant melanoma 
cells. To get further insight into the perspective of 
potential clinical GLUT1 inhibitory strategies, we 
applied WZB117, a new, highly specific small-molecule 
inhibitor of GLUT1 [25], to the human melanoma cell 
lines WM3211, Mel-Im and SbCl2 in vitro. In all cell 
lines, incubation with WZB117 led to a dose-dependent 
reduction of glucose consumption and lactate secretion 
without affecting LDH levels in the supernatant (Suppl.
Figure 8A-8C). Furthermore, pharmacological GLUT1 
inhibition with WZB117 reduced proliferation (Figure 
5A, Suppl.Figure 9A) and XTT activity (Figure 5B, Suppl.
Figure 9B) of human melanoma cells in vitro. Conversely, 
the proportion of apoptotic cells was increased when cells 
were treated with WZB117 (Figure 5C, Suppl.Figure 9C). 
In addition, WZB117 decreased the migratory activity of 
human melanoma cells as shown by Boyden chamber and 
time-lapse scratch assays (Figure 5D, 5E, Suppl.Figure 
10A, 10B). WZB117 treatment also led to a significantly 
reduced MMP2 expression (Figure 5F, Suppl.Figure 
10C). Western blot analysis revealed decreased amounts 
of phosphorylated JNK and c-JUN in melanoma cells 
treated with WZB117 (Figure 5G, Suppl.Figure 10D). 
Importantly, incubation of primary human hepatocytes 
with WZB117 in even higher doses than applied in 
melanoma cells did not decrease viability or glucose 
uptake (data not shown). In summary, pharmacological 
GLUT1 inhibition in human melanoma cells revealed 
comparable anti-tumorigenic effects as observed in murine 
B16 melanoma cells with shRNA-suppressed GLUT1 
expression.
DISCUSSION
Malignant melanomas have unique tumor biology 
and unpredictable patterns of metastasis. The aim of 
this study was to analyze the expression and function of 
GLUT1 in the progression of this highly aggressive form 
of skin cancer.
Increased GLUT1 expression has been demonstrated 
in several types of human tumors compared to non-
cancerous tissues [7, 8, 24, 26-28]. However, most of the 
published reports studied epithelial neoplasms, whereas 
nevi and malignant melanomas arise from melanocytes, 
which originate from the neural crest, and it is well known 
that melanocytes and derived cancerous cells have unique 
metabolic pathways that may interfere with glycolysis. 
Previous studies of GLUT1 expression in melanoma 
have shown inconclusive and in part opposite results. 
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Figure 4: Effect of GLUT1 inhibition on hepatic metastasis of B16 melanoma cells in vivo. Hepatic metastasis of GLUT1 
suppressed and control B16 cell clones were analyzed in a syngeneic model in Bl6/N mice. A. Representative images of macroscopically 
visible metastases on the liver surface (left panel). Bar graphs depicting the number of metastases derived from GLUT1 suppressed 
and control cell clones on the liver surface (control set 1) (right panel). B. Representative images of HE stained hepatic tissue sections 
showing intrahepatic metastases (left panel). Bar graphs depicting the number of intrahepatic metastases formed by GLUT1 suppressed 
and control cell clones (control set 1) (right panel). C. Immunohistochemical GLUT1 staining of hepatic metastases (*: central necrosis). 
Squares depict areas which are shown as higher-magnification field in the lower panel. D. quantitative RT-PCR analysis of GLUT1 mRNA 
expression in hepatic metastases. E. TUNEL staining of hepatic metastases derived from GLUT1 suppressed and control cell clones (left 
panel). Bar graphs depicting the number of TUNEL positive cells (control set 1) (right panel). (*p < 0.05 compared to control).
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Applying western blot technique, Wachsberger et al. 
observed a strong variation in GLUT1 levels in primary 
melanoma tissues but did not compare expression levels 
with non-malignant tissues [17]. Baer et al. and Parente 
et al. reported less frequent GLUT1 in melanomas as 
compared to melanocytic nevi and the majority of Spitz 
nevi [18, 29]. However, they analyzed only small numbers 
of specimens. In contrast, a recent study by Slominski et 
al. showed significantly higher levels of GLUT1 in 75 
melanomas compared to 26 melanocytic nevi [19]. Here, 
we confirmed the increased GLUT1 expression in 78 
melanomas compared with 128 nevi. Most importantly, 
we found that GLUT1 expression in primary melanomas 
was an indicator for progression free- and overall survival. 
Previous studies reported various associations between 
GLUT1 expression and tumor aggressiveness and a poor 
prognosis in a number of other malignancies including 
pancreatic, pulmonary, colorectal, hepatocellular, 
ovarian and squamous cell carcinoma [27, 28, 30-32]. 
One explanation for the correlation between GLUT1 
expression and a poor prognosis in melanoma and other 
types of cancer may be an increased utilization of energy 
and faster cell growth. Indeed, we and others have shown 
in the past that GLUT1 expression levels in various cancer 
cell types correlate with induced glycolytic activity and 
increased proliferation [14, 26, 33, 34]. Here, we show 
Figure 5: Effect of a chemical GLUT1 inhibition on human melanoma cells in vitro. The human melanoma cell line WM3211 
was treated with the chemical GLUT1 inhibitor WZB117 at the concentrations indicated. A. Proliferation analyzed with XCELLigence™ 
system, B. XTT activity and C. proportion of apoptotic cells (Annexin V-FITC FACS analysis). Migratory activity analyzed with D. 
Boyden chamber and E. time-lapse scratch assays (bar depicts the original width of the scratch), and F. MMP2 mRNA expression levels. 
G. Western blot analysis of phosphorylated JNK1/2 (Thr183/Tyr185) and c-JUN (Ser73). (*p < 0.05 compared to control).
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that also in melanoma cells GLUT1 expression promotes 
glucose uptake and cell growth. And also in human 
melanoma tissues, we found a significant correlation 
between GLUT1 expression and mitotic activity. Thus, 
induction of the growth of the primary tumor appears as 
one mechanism by which GLUT1 expression induces 
melanoma progression and metastasis.
In addition, we identified further mechanisms by 
which GLUT1 levels induce metastasis of melanoma 
cells. Matrix metalloproteinases (MMPs) are degradative 
enzymes that play an important role in all aspects of tumor 
progression by enhancing tumor-induced angiogenesis. 
Furthermore, MMPs destroy the local tissue architecture 
and basement membranes allowing tumor invasion and 
metastasis [35]. Here, we demonstrate that inhibition of 
GLUT1 inhibition lowers MMP2 expression in melanoma 
cells. MMP2 has been shown to be associated with 
melanoma progression [36, 37]. Moreover, we newly 
found that GLUT1 inhibits apoptosis of melanoma cells 
in vitro and in vivo. Hereby, we identified one further 
mechanism by which GLUT1 promotes melanoma 
growth and metastasis. JNK regulates a wide range of 
targets in the metastatic cascade [21]. Also in melanoma, 
this pathway is a critical regulator of tumor progression 
[22, 38]. Noteworthy, we observed that GLUT1 inhibition 
caused a significant inhibition of JNK-activity. To the 
best of our knowledge, impairment of glycolysis or 
components of the glycolytic cascade, respectively, has 
not been connected with MAPK-activity. Our data indicate 
that the protumorigenic effects of GLUT1 in melanoma 
are at least in part mediated via JNK-activation.
In the light of the direct impact of GLUT1 
expression on different protumorigenic mechanisms 
in melanoma, it was important that we further found 
that melanoma metastases revealed stronger GLUT1 
expression than primary human melanomas, which was 
in line with a previous study from Mihic-Probst et al. 
[39]. The focus of this elegant study was vasculogenic 
mimicry and neovascularization in human melanoma, and 
the authors observed an inverse correlation between blood 
vessel number and GLUT1 expression. Consequently, 
they suggested that the hypoxic microenvironment in 
metastases contributes to GLUT1 expression. Moreover, 
Lee et al. analyzed GLUT1 expression in pulmonary 
metastases of melanoma patients and found that 
GLUT1 staining intensity was a significant predictor of 
postmetastasectomy survival [40]. Together with our new 
findings in melanoma, these studies indicate that there may 
be at least two mechanisms which explain higher GLUT1 
expression in melanoma metastases: (i) origin from 
primary tumors with already higher expression levels and 
(ii) additional induction by hypoxia or other environmental 
factors at the place of metastasis. Furthermore, these 
data indicate GLUT1 expression in primary tumors and 
melanoma metastases as potential prognostic marker or 
marker for therapeutic decisions, respectively. If biopsied 
tissue is not available, 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET) can be used for clinical 
evaluation and quantification of glycolytic phenotype and 
a surrogate for GLUT1 expression in malignant melanoma 
(metastases). Park et al. described a positive correlation 
between FDG uptake and GLUT1 expression in metastases 
of melanoma patients [15]. Also several other reports 
indicate that the expression of GLUT1 correlates with 
the uptake of the glucose analogue 18F-FDG in a variety 
of human tumors [41-43]. Moreover, Baudy et al. found 
that 18F-FDG can be a sensitive biomarker for assessing 
efficacy and also resistance to the BRAF inhibitor 
vemurafenib [44]. Mechanistically, they found that this 
resistance was associated with the induction of GLUT1. 
Other studies indicate that FDG-PET correlated with 
the response to further classes of chemotherapeutics in 
melanoma patients [45, 46]. Furthermore, Giammarioli et 
al. showed that inhibition of glucose metabolism by using 
glucose analogue 2-Deoxy-D-glucose acted synergistic 
with cisplatin against melanoma cells in vitro [47]. Still, 
to the best of our knowledge there are no studies analyzing 
the effect of GLUT1 inhibition in melanoma cells on 
the efficacy of chemotherapeutic agents and on therapy 
resistance, respectively. However, studies in several other 
cancer cells such as colon, hepatocellular, head and neck 
or oral squamous cell carcinoma indicate that GLUT1 
inhibition may be considered an additional treatment 
option for resistant forms of cancers [48-50].
The therapeutic potential of GLUT1 inhibitory 
strategies alone or together with other therapeutic 
strategies in (metastatic) melanoma is yet to be determined, 
but our data provide additional evidence to pursue such 
studies. Furthermore, our findings promote GLUT1 levels 
in primary melanoma tissues as well as in metastases as a 
prognostic marker for this highly aggressive tumor.
MATERIALS AND METHODS
Cells and cell culture
The murine melanoma cell line B16 and the human 
melanoma cell lines Mel-Im, SbCl2 and WM3211 were 
cultured as described [23]. For some experiments, cells 
were treated with the small-molecule GLUT1-inhibitor 
WZB117 (EMD Chemicals, San Diego, CA, USA) 
[25] with different concentrations and time periods as 
indicated. The vehicle DMSO alone served as control. 
Stable transfection of B16 melanoma cells
A panel of B16 cell clones with decreased GLUT1 
expression were established by stable transfection with 
short hairpin RNA (shRNA) plasmids containing either 
antisense GLUT1-shRNA and neomycin resistance 
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(shRNA1, shRNA2; Sure Silencing shRNA Plasmid, 
Mouse Slc2a1, Qiagen, Hilden, Germany) or neomycin 
resistance alone (ctrl; Sure Silencing shRNA Plasmid, 
Negative Control-Neomycin, Qiagen) as described [23]. 
Paraffin-embedded pellets of cultured cells were generated 
using Shandon Cytoblock Cell Block Preparation System 
(Thermo Scientific, Waltham, MA, USA) according to the 
supplier’s instructions.
Human malignant melanoma tissue micro array 
(TMA)
A tissue micro array (TMA) comprising specimens 
from benign nevi, primary human melanoma and 
melanoma metastases was constructed as described [20]. 
Clinicopathological patient characteristics are summarized 
in Table 1. The median follow up for all patients was 
54 months (range 1-135 months). The University of 
Regensburg Institutional Review Board granted approval 
for the project.
Analysis of mRNA expression
Isolation of total cellular RNA from cells and tissues 
and reverse transcription were performed as described 
[51]. Quantitative real-time PCR was performed applying 
LightCycler technology (Roche, Mannheim, Germany) 
[51] and the following pairs of primers: human GLUT1 
(forward: 5’- AAC TCT TCA GCC AGG GTC CAC; 
reverse: 5’-CAC AGT GAA GAT GAT GAA GAC) and 
human MMP2 (forward: 5’-GCT GGG AGC ATG GCG 
ATG GAT ACC-3’; reverse: 5’-GGA CAG AAG CCG 
TAC TTG CCA TCC-3’). Murine GLUT1 and murine 
MMP2 mRNA expression analyses were performed using 
QuantiTect Primer Assays according to the manufacturer’s 
instructions (Qiagen). Amplification of cDNA derived 
from 18S rRNA (forward: 5’-AAA CGG CTA CCA CAT 
CCA AG-3’; reverse: 5’-CCT CCA ATG GAT CCT CGT 
TA-3’) was used for normalization. 
Protein analysis
Protein extraction and western blotting were 
performed as described [51] applying the following 
primary antibodies: rabbit polyclonal anti-GLUT1 
(Thermo Scientific, RB-9052, 1 : 1,000), rabbit 
polyclonal anti-phospho-SAPK/JNK (Cell Signaling 
Technology, Leiden, The Netherlands; #9251, 1 : 1,000), 
rabbit monoclonal anti-phospho-c-JUN (Cell Signaling 
Technology, #3270, 1 : 1,000) and mouse monoclonal 
anti-Actin (ACTB; Merck Millipore, Billerica, MA, 
USA; MAB1501, 1 : 10,000). Goat anti-rabbit (Santa Cruz 
Biotechnology, Heidelberg, Germany; sc-2030, 1 : 2,500) 
and goat anti-mouse (Santa Cruz Biotechnology, sc-2005, 
1 : 2,500) were used as secondary antibodies.
Histological and immunohistological analyses
For immunohistochemistry and hematoxylin and 
eosin (HE) staining, standard 5 µm sections of formalin-
fixed and paraffin-embedded tissue blocks were used. 
Immunohistochemical staining was performed using 
the following antibodies as described [51]: anti-GLUT1 
(Thermo Scientific, RB-9052, 1 : 100), anti-KI67 (Abcam, 
Cambridge, UK; MIB1, 1 : 50). Immunohistochemical 
stainings were counterstained with hematoxylin. For 
analysis of the TMA, GLUT1 staining intensity was 
scored semiquantitatively as 0, 1 or 2. The staining 
intensity was defined as negative (score 0), weak (score 1) 
and strong (score 2) with reference to the immunostaining 
of erythrocytes, which were scored as strong. The GLUT1 
score was specified based on the staining intensity of the 
majority of melanoma cells. Representative examples of 
melanoma specimens with these three GLUT1 staining 
intensities are depicted in Figure 1A (right panel).
Glucose uptake
Glucose uptake was measured by incubating cells 
with 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-
Deoxyglucose (2-NBDG; Thermo Scientific N13195) and 
subsequent fluorescence-activated cell sorting (FACS) 
analysis as described [26].
Proliferation and mitochondrial activity assays
Cell proliferation was measured using the 
xCELLigence system (Roche) according to the 
manufacturer’s instructions. In addition, cell proliferation 
was determined by cell counting. Here, 1 x 106 cells were 
seeded into T75 flasks. After 48h, cells were trypsinized 
and microscopically counted. Mitochondrial activity was 
measured applying a colorimetric XTT assay (Roche) 
[51].
Caspase-3/7 activity assay, annexin V-FITC FACS 
analysis and TUNEL assay
Caspase-3/7 activity was analyzed using the 
Apo-One homogeneous caspase-3/7 assay (Promega, 
Mannheim, Germany) as described [52]. For detection 
of apoptosis, cells were stained simultaneously with 
FITC-conjugated Annexin V and propidium iodide (both 
Promokine, Heidelberg, Germany) and analyzed by flow 
cytometry as described [52]. Flowing Software™ version 
2.51 (Perttu Terho, Turku, Finland) was used for FACS 
data analysis. Terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling staining (TUNEL, 
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Promega) was performed according to the manufacturer’s 
instructions. For statistical analysis, TUNEL positive cells 
were counted in 4 representative sections per sample. 
Analysis of migratiory activity of melanoma cells 
in vitro
Migratory activity of melanoma cells was quantified 
using Cultrex 96 Well Cell Migration assay (Trevigen, 
Gaithersburg, MD, USA) as described [26]. Further, cell 
migration was assessed applying time-lapse scratch assays 
(‘wound-healing-assay’) as described [53]. Briefly, nearly 
confluent cell monolayers were scratched and migration 
of cells into the wounded area was monitored throughout 
a 24h time window. 
In vivo metastasis assay
To determine the metastatic potential of murine 
B16 melanoma cells in vivo, a mouse model of hepatic 
metastasis was used [23]. Monodispersed tumor cells (1 
x 106 in 50µl) were injected into the spleen of syngeneic 
Bl/6N mice (n = 7 per group; age: 16 weeks, mean 
bodyweight: 24g; Charles River Laboratories, Sulzfeld, 
Germany). After 11 days, mice were sacrificed and the 
livers were processed for further analyses.
All experimental protocols were approved by 
the Committee on Animal Health and Care of the local 
government, and conformed to international guidelines on 
the ethical use of animals.
Statistical analysis and image acquisition tools
Results are expressed as mean ± SEM. Comparison 
between groups was made using ordinary one-way 
ANOVA. A p-value < 0.05 was considered statistically 
significant. Contingency table analysis and two-sided 
Fisher’s exact tests were used to study the statistical 
association between categorical clinicopathological 
and immunohistochemical variables. Retrospective 
overall survival and progression-free survival curves 
comparing patients with and without any of the variables 
were calculated using the Kaplan-Meier method, with 
significance evaluated using log-rank statistics. For the 
progression-free survival analysis, patients were censored 
at the time of their last tumor-free clinical follow-up 
appointment. For the overall survival analysis, patients 
were censored at the time of their last clinical follow-up 
appointment. Median overall survival time for censored 
patients was 63.5 months (range: 3-135 months). 
Calculations were performed by using the GraphPad 
Prism Software version 6.01 (GraphPad Software, San 
Diego, CA, USA) and SPSS Software version 21.0 (SPSS, 
Chicago, IL, USA).
Microscopical images were taken using an 
Olympus™ CKX41 microscope with the ALTRA 20 
Soft Imaging System™ and CellA software version 2.6 
(Olympus Soft Imaging Solutions GmbH, Münster, 
Germany). Images were processed using IrfanView™ 
software version 4.36 (Irfan Skiljan, Jajce, Bosnia).
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